Alnylam Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Reata Pharmaceuticals, Celyad, Sorrento Therapeutics, CureVac, Sarepta Therapeutics and Ionis Pharmaceuticals.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 | Founding Date 2000 | Founding Date 1980 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations Carlsbad, US HQ | |
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 1751% decrease | Employees 31019% decrease | Employees 999 | Employees 1,31413% increase | Employees 92716% increase |
Valuation ($) | Valuation ($) 35.3 b | Valuation ($) 6.6 b | Valuation ($) N/A | Valuation ($) 2.2 m | Valuation ($) 686.4 m | Valuation ($) 11.9 b | Valuation ($) 6.5 b |
Financial | |||||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) $1.2b (FY, 2023) | Revenue (est.) $787.6m (FY, 2023) |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods €64.3m (FY, 2023) | Cost of goods $150.3m (FY, 2023) | Cost of goods $9.1m (FY, 2023) |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) | Gross profit $1.1b (FY, 2023) | Gross profit $778.5m (FY, 2023) |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income (€260.2m) (FY, 2023) | Net income ($536m) (FY, 2023) | Net income ($366.3m) (FY, 2023) |
Operating ⚠ | |||||||
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued 233 (May, 2020) | Patents Issued N/A | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 13 (FY, 2023) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2023) |
Funding | |||||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.1b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Reata Pharmaceuticals
HQ
Plano, US
Employees
321↓ 7% decrease
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company
CureVac
HQ
Tübingen, DE
Employees
999
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View company